This invention relates to a novel use of IL-1 .beta.-Iigand/IL-1 receptor disrupting compounds (herein referred to as "IL-1 beta Compounds")； such as small molecular compounds disrupting IL-1 .beta. ligand - IL-1 receptor interaction, IL-1 .beta. antibodies or IL-1 receptor antibodies, e.g. IL-1 .beta. binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1 .beta. binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1 .beta. ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
